These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29741961)

  • 21. Functionalized imidazolium and benzimidazolium salts as paraoxonase 1 inhibitors: Synthesis, characterization and molecular docking studies.
    Karataş MO; Uslu H; Alıcı B; Gökçe B; Gencer N; Arslan O; Arslan NB; Özdemir N
    Bioorg Med Chem; 2016 Mar; 24(6):1392-401. PubMed ID: 26879855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impacts of some antibiotics on human serum paraoxonase 1 activity.
    Dilek EB; Küfrevioğlu Öİ; Beydemir Ş
    J Enzyme Inhib Med Chem; 2013 Aug; 28(4):758-64. PubMed ID: 22591317
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Sever B; Kucukoglu K; Nadaroglu H; Altıntop MD
    Curr Comput Aided Drug Des; 2019; 15(2):136-144. PubMed ID: 29773067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of in vitro effect, molecular docking, and molecular dynamics simulations of some dihydropyridine-class calcium channel blockers on human serum paraoxonase 1 (hPON1) enzyme activity.
    Gökçe B; Muhammed MT
    Biotechnol Appl Biochem; 2023 Oct; 70(5):1707-1719. PubMed ID: 37071114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory Effects of Usnic and Carnosic Acid on Some Metabolic Enzymes: An In vitro Study.
    Ceylan H; Demir Y; Beydemir Ş
    Protein Pept Lett; 2019; 26(5):364-370. PubMed ID: 30827223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro effects of thirty-eight cardiac drugs on human serum paraoxonase.
    Argan O; Cikrikci K; Uslu H; Gencer N
    Chem Biol Drug Des; 2022 Jul; 100(1):80-89. PubMed ID: 35395139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naphthoquinones, benzoquinones, and anthraquinones: Molecular docking, ADME and inhibition studies on human serum paraoxonase-1 associated with cardiovascular diseases.
    Demir Y
    Drug Dev Res; 2020 Aug; 81(5):628-636. PubMed ID: 32232985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro efficacy of some cattle drugs on bovine serum paraoxonase 1 (PON1) activity.
    Arslan M; Gencer N; Arslan O; Guler OO
    J Enzyme Inhib Med Chem; 2012 Oct; 27(5):722-9. PubMed ID: 21985443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naringenin is an inhibitor of human serum paraoxonase (PON1): an in vitro study.
    Mahrooz A; Rashidi MR; Nouri M
    J Clin Lab Anal; 2011 Nov; 25(6):395-401. PubMed ID: 22086792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo.
    Alici HA; Ekinci D; Beydemir S
    Clin Biochem; 2008 Nov; 41(16-17):1384-90. PubMed ID: 18640108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lactoperoxidase, an antimicrobial enzyme, is inhibited by some indazoles.
    Köksal Z; Alim Z
    Drug Chem Toxicol; 2020 Jan; 43(1):22-26. PubMed ID: 30126312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An alternative purification method for human serum paraoxonase 1 and its interactions with sulfonamides.
    Ekinci D; Sentürk M; Beydemir S; Küfrevioğlu OI; Supuran CT
    Chem Biol Drug Des; 2010 Dec; 76(6):552-8. PubMed ID: 21040495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards Understanding the Catalytic Mechanism of Human Paraoxonase 1: Experimental and In Silico Mutagenesis Studies.
    Tripathy RK; Aggarwal G; Bajaj P; Kathuria D; Bharatam PV; Pande AH
    Appl Biochem Biotechnol; 2017 Aug; 182(4):1642-1662. PubMed ID: 28161867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases.
    Ekinci D; Beydemir S
    Eur J Pharmacol; 2009 Sep; 617(1-3):84-9. PubMed ID: 19577563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of some analgesics on paraoxonase-1 purified from human serum.
    Ekinci D; Beydemir S
    J Enzyme Inhib Med Chem; 2009 Aug; 24(4):1034-9. PubMed ID: 19548782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics.
    Sinan S; Kockar F; Arslan O
    Biochimie; 2006 May; 88(5):565-74. PubMed ID: 16600468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ophthalmic drugs: in vitro paraoxonase 1 inhibition and molecular docking studies.
    Çalışkan B; Demir Y; Türkeş C
    Biotechnol Appl Biochem; 2022 Dec; 69(6):2273-2283. PubMed ID: 34786760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium.
    Türkeş C; Söyüt H; Beydemir Ş
    J Enzyme Inhib Med Chem; 2015; 30(4):622-8. PubMed ID: 25519764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lyso-DGTS lipid isolated from microalgae enhances PON1 activities in vitro and in vivo, increases PON1 penetration into macrophages and decreases cellular lipid accumulation.
    Dahli L; Atrahimovich D; Vaya J; Khatib S
    Biofactors; 2018 May; 44(3):299-310. PubMed ID: 29659105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of selective serotonin reuptake inhibitors on paraoxonase-1 enzyme activity: An in vitro study.
    Demir Y; Balcı N; Gürbüz M
    Comp Biochem Physiol C Toxicol Pharmacol; 2019 Dec; 226():108608. PubMed ID: 31422163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.